Off-label medicine combinations are the predominant treatment in survey of schizophrenics
Off-label medication use, the clinical application of prescribed drugs for indications other than those approved by the relevant drug regulatory agency (in the US, the Food and Drug Administration—FDA), is widespread in many areas of medicine but is particularly common in psychiatry. While off-label uses are legal and in many instances may be in the best interests of patients, they have not received the same degree of independent scrutiny through randomized clinical trials as have approved indications. A drug approved for marketing may be labeled, promoted and advertised by the manufacturer for only those uses for which the drug's safety and effectiveness have been established by the FDA. In a new paper, published in the online, open-access journal PLoS ONE, David Pickar and colleagues, of Gabriel Sciences, report that 74.5% of 200 community-based schizophrenic patients, who were individually interviewed and evaluated (including a review of clinical records), were treated with off-label medication treatments. Specifically, 42.5% of subjects reported that they were simultaneously treated with more than one antipsychotic drug, an unapproved treatment for schizophrenia. The most common unapproved drug combination was the use of both an antipsychotic drug and a mood stabilizer (45% of patients). This combination of drug classes was predicted by the diagnosis of schizoaffective schizophrenia, history of having physically hurt someone and high symptom ratings.
The sample of schizophrenic patients studied in this report was derived from multiple outpatient settings and reflect demographies of seriously ill patients with schizophrenia. For example, there was a slightly higher male prevalence (59.5%); largely, patients were never married (75%); a majority live in supervised dwelling (54.5%); nearly half had had involuntary hospitalizations (47.5%), and had made a suicide attempt (48%); the mean age of onset was 19.9 years. The economic implications of off-label medication use are substantial for public sector payers as well as for the revenue of the pharmaceutical industry, whose promotion of off-label drug use is of considerable concern.
"These data underscore the limitations of both first and second generation antipsychotic drugs and the desire of clinicians to improve outcome in schizophrenic patients. The off-label status of the drug treatments are problematic as, studies required to establish support are both expensive and expose risk to the company's market by the possibility of new or serious adverse events and/or not being able to establish efficacy. Since a company is not allowed to promote an off-label use, the importance of so-called opinion leaders, who are free to independently discuss treatment approaches, increases substantially. The financial opportunities for both the company and the opinion leader can lead to blurred boundaries," observed senior author David Pickar, MD, President of Gabriel Sciences and Adjunct Professor, Johns Hopkins Medical School.
Source: Public Library of Science
- Building a better antipsychotic drug by treating schizophrenia's cause Wed, 24 Aug 2011, 10:34:57 EDT
- Combating weight gain caused by antipsychotic treatmentsThu, 26 Mar 2009, 2:44:15 EDT
- Blood pressure drug combination reduces heart attack deathsTue, 16 Sep 2008, 13:45:51 EDT
- 14 drugs identified as most urgently needing study for off-label use, Stanford professor saysMon, 24 Nov 2008, 13:22:08 EST
- Drug combination improves or stabilizes disease for relapsed multiple myeloma patientsTue, 9 Dec 2008, 13:19:04 EST
- Off-label Medicine Combinations Are Predominant Treatment In Survey Of Schizophrenicsfrom Science DailyFri, 12 Sep 2008, 10:35:21 EDT
- Off-label medicine combinations are the predominant treatment in survey of schizophrenicsfrom Science CentricThu, 11 Sep 2008, 17:00:21 EDT
- Off-label medicine combinations are the predominant treatment in survey of schizophrenicsfrom PhysorgWed, 10 Sep 2008, 9:50:56 EDT
Latest Science NewsletterGet the latest and most popular science news articles of the week in your Inbox! It's free!
Learn more about
Check out our next project, Biology.Net
From other science news sites
Popular science news articles
- Researchers reveal model of Sun's magnetic field
- 2 miniature spider species discovered in Giant Panda Sanctuaries of China
- The Norway spruce genome sequenced
- UCLA life scientists present new insights on climate change and species interactions
- Baby's life saved with groundbreaking 3-D printed device that restored his breathing
- Allosaurus fed more like a falcon than a crocodile, new study finds
- Invasive crazy ants are displacing fire ants in areas throughout southeastern US
- Beautiful 'flowers' self-assemble in a beaker
- Scientific insurgents say 'Journal Impact Factors' distort science
- GPS solution provides 3-minute tsunami alerts